4,6-hexadecadiene-2,4-dicarboxylic acid derivative
View Patent ↗A 4,6-hexadecadiene-2,4-dicarboxylic acid derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, each of which has an anti-tumor activity, and the like, are provided. [wherein, R 1 represents hydroxy, —OR 3 (wherein R 3 represents optionally substituted lower alkyl or an optionally substituted aliphatic heterocyclic group), or —NR 4 R 5 (wherein R 4 and R 5 may be the same or different, and each represents a hydrogen atom or optionally substituted lower alkyl) and R 2 represents hydroxy or —OR 6 (wherein R 6 represents optionally substituted lower alkyl or optionally substituted aralkyl)].
1. A 4,6-hexadecadiene-2,4-dicarboxylic acid derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof
[wherein R 4 represents hydroxy, -0R 3 (wherein R 3 represents optionally substituted lower alkyl or an optionally substituted aliphatic heterocyclic group), or —NR 4 R 5 (wherein R 4 and R 5 may be the same or different, and each represents a hydrogen atom or optionally substituted lower alkyl) and
R 2 represents hydroxy or —OR 6 (wherein R 6 represents optionally substituted lower alkyl or optionally substituted aralkyl)].
2. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is hydroxy.
3. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is —OR 6 (wherein R 6 represents optionally substituted lower alkyl or optionally substituted aralkyl).
4. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 3 , wherein R 6 is optionally substituted lower alkyl.
5. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 3 , wherein R 6 is substituted lower alkyl.
6. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 3 , wherein R 6 is acetoxymethyl.
7. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is hydroxy.
8. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is -0R 3 (wherein R 3 represents optionally substituted lower alkyl or an optionally substituted aliphatic heterocyclic group).
9. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is an optionally substituted aliphatic heterocyclic group.
10. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is optionally substituted tetrahydrofuranyl.
11. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is optionally substituted oxotetrahydrofuranyl.
12. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is oxotetrahydrofuranyl substituted with carboxy.
13. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is optionally substituted lower alkyl.
14. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is substituted lower alkyl.
15. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 8 , wherein R 3 is substituted propyl.
16. The 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the 4,6-hexadecadiene-2,4-dicarboxylic acid derivative is selected from 4-{(4Z,6E)-4-carboxy-2,6,8,10,12,14-hexamethylhexadec-4,6-dienoyloxy}-5-oxotetrahydrofuran-2,3-dicarboxylic acid and 1-{(4Z,6E)-4-carboxy-2,6,8,10,12,14-hexamethylhexadec-4,6-dienoyloxy}-3-hydroxypropane-1,2,3-tricarboxylic acid.
17. A pharmaceutical composition comprising, as an active ingredient, the 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 .
18. A method for inhibiting the growth of cervical cancer cells comprising a step of administering an effective amount of the 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1 .